NEW YORK – Merck and Moderna announced Wednesday that a Phase III melanoma trial of Keytruda (pembrolizumab) and the personalized cancer vaccine intismeran autogene has met two key endpoints.

The firms will evaluate Ideaya's IDE892 with Genetech's GDC-7035 in MTAP-deleted, KRAS G12D-mutant pancreatic cancer.

The CAR T-cell therapy is the world's first approved for solid tumors and is being tested in a US-based trial.

The firm will use the proceeds to advance neuro-metabolic therapies, including a Phase I/II trial of an antisense oligonucleotide for ALS.

NEW YORK – Eli Lilly has acquired global rights to AlzeCure Pharma's preclinical Alzheimer's disease drug candidate ACD680 after paying the company $10 million upfront, the companies said Tuesday.

The firm reported $11.4 million in net revenue from Zevaskyn for the three months ended June 30, missing analysts' expectations of roughly $12.3 million.

The Chinese biotech said US regulators have cleared it to start trials of the therapy for patients with B-cell lymphoma.

PMC's new president and CEO said the organization is expanding beyond oncology, engaging with Capitol Hill, and challenging a controversial research grant rule.

NEW YORK – AstraZeneca on Monday indicated it would seek to expand Enhertu (trastuzumab deruxtecan) and a Tagrisso (osimertinib) combination into new biomarker-defined lung cancer indications based on ...

NEW YORK – Epicrispr Biotechnologies has raised $90 million in an oversubscribed Series C funding round to advance its pipeline of epigenetic medicines that regulate gene expression. The Series C ...

The investigator-initiated trial comes after Elicio said a Phase II trial of ELI-002 7P in adjuvant pancreatic cancer did not meet its primary endpoint.